Bicycle Therapeutics PLC Share Price Today: Live Updates & Key Insights

Bicycle Therapeutics PLC share price today is $4.39, up -4.4%. The stock opened at $4.45 against the previous close of $4.55, with an intraday high of $4.6108 and low of $4.295.

Bicycle Therapeutics PLC Share Price Chart

Bicycle Therapeutics PLC

us-stock
To Invest in {{usstockname}}
us-stock

Bicycle Therapeutics PLC Share Price Performance

$4.39 -0.044(-4.4%) BCYC at 23 Mar 2026 12:10 PM Biotechnology
Lowest Today 4.295
Highest Today 4.6108
Today’s Open 4.45
Prev. Close 4.55
52 Week High 9.69
52 Week Low 4.30
Day’s Range: Low 4.295 High 4.6108
52-Week Range: Low 4.30 High 9.69
1 day return -
1 Week return -13.69
1 month return -19.44
3 month return -39.24
6 month return -38.94
1 year return -52.66
3 year return -78.98
5 year return -83.2
10 year return -

Bicycle Therapeutics PLC Institutional Holdings

Baker Bros Advisors LP 15.69

FCPM III SERVICES BV 4.98

Armistice Capital, LLC 4.67

Westfield Capital Management Company, L.P. 4.35

Siren, L.L.C. 2.90

Long Focus Capital Management, LLC 2.35

T. Rowe Price Associates, Inc. 2.00

Acadian Asset Management LLC 1.90

Candriam Luxembourg S.C.A. 1.72

Principal Financial Group Inc 1.66

Harbor Small Cap Growth Instl 1.47

Westfield Capital Mgt Co Sm-Cap Gr Eq 1.47

Candriam Eqs L Biotech C USD Cap 1.19

Morgan Stanley - Brokerage Accounts 1.19

T. Rowe Price Health Sciences 1.15

Bank of America Corp 0.85

Schroder Investment Management Group 0.84

BNP Paribas Health Cr Innovtr Cl Cap 0.82

Principal SmallCap R5 0.82

Principal U.S. Small Cap Equity 0.82

Principal U.S. Small Cap Select Equity 0.82

Renaissance Technologies Corp 0.82

Silvercrest Asset Management Group LLC 0.69

Birchview Capital, LP 0.67

Point72 Asset Management, L.P. 0.62

Jefferies Financial Group Inc 0.58

Belfius Equities Cure C Cap 0.53

Millennium Management LLC 0.47

BlackRock Inc 0.41

iShares Biotechnology ETF 0.37

Old Westbury Small & Mid Cap Strategies 0.31

Westfield Small/Mid Cap Grow Eq CIT CL C 0.28

Silvercrest U.S. Small Cap Growth 0.20

Principal SmallCap SP 0.17

TD Health Sciences - I 0.14

BlueBox Precision Medicine S USD Acc 0.13

T. Rowe Price Health Sciences Port 0.09

Principal VC SmallCap 1 0.07

ALPS Medical Breakthroughs ETF 0.06

SEB Concept BioTech Acc ob 0.06

Bicycle Therapeutics PLC Market Status

Strong Buy: 5

Buy: 5

Hold: 3

Sell: 0

Strong Sell: 0

Bicycle Therapeutics PLC Fundamentals

Market Cap 301.75 M

PB Ratio 0.5092

PE Ratio 0.0

Enterprise Value -309.51 M

Total Assets 717.60 M

Volume 975895

Bicycle Therapeutics PLC Company Financials

Annual Revenue FY24:35275000 35.3M, FY23:24830000 24.8M, FY22:14463000 14.5M, FY21:11697000 11.7M, FY20:10390000 10.4M

Annual Profit FY24:35275000 35.3M, FY23:null 0.0M, FY22:14463000 14.5M, FY21:11697000 11.7M, FY20:10390000 10.4M

Annual Net worth FY24:-169031000 -169.0M, FY23:-161543000 -161.5M, FY22:-112717000 -112.7M, FY21:-66819000 -66.8M, FY20:-51010000 -51.0M

Quarterly Revenue Q3/2025:11734000 11.7M, Q2/2025:2920000 2.9M, Q1/2025:9977000 10.0M, Q3/2024:2676000 2.7M, Q2/2024:9371494 9.4M

Quarterly Profit Q3/2025:11734000 11.7M, Q2/2025:-68109000 -68.1M, Q1/2025:-47294000 -47.3M, Q3/2024:481724 0.5M, Q2/2024:7729656 7.7M

Quarterly Net worth Q3/2025:-59100000 -59.1M, Q2/2025:-78952000 -79.0M, Q1/2025:-60754000 -60.8M, Q3/2024:-50802000 -50.8M, Q2/2024:-39856630 -39.9M

About Bicycle Therapeutics PLC & investment objective

Company Information Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Organisation Biotechnology

Employees 305

Industry Biotechnology

CEO Dr. Kevin Lee M.B.A., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Bicycle Therapeutics PLC FAQs

What is the share price of Bicycle Therapeutics PLC today?

The current share price of Bicycle Therapeutics PLC is $4.39.

Can I buy Bicycle Therapeutics PLC shares in India?

Yes, Indian investors can buy Bicycle Therapeutics PLC shares by opening an international trading and demat account with Motilal Oswal.

How to buy Bicycle Therapeutics PLC shares in India?

You can easily invest in Bicycle Therapeutics PLC shares from India by:

Can I buy fractional shares of Bicycle Therapeutics PLC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Bicycle Therapeutics PLC?

Bicycle Therapeutics PLC has a market cap of $301.75 M.

In which sector does Bicycle Therapeutics PLC belong?

Bicycle Therapeutics PLC operates in the Biotechnology sector.

What documents are required to invest in Bicycle Therapeutics PLC stocks?

To invest, you typically need:

What is the PE and PB ratio of Bicycle Therapeutics PLC?

The PE ratio of Bicycle Therapeutics PLC is N/A and the PB ratio is 0.51.